## KIF18A-IN-2

| Cat. No.:          | HY-145802                           |       |          |  |
|--------------------|-------------------------------------|-------|----------|--|
| CAS No.:           | 2600559-20                          | -2    |          |  |
| Molecular Formula: | $C_{25}H_{34}N_4O_5S_2$             |       |          |  |
| Molecular Weight:  | 534.69                              |       |          |  |
| Target:            | Microtubule/Tubulin                 |       |          |  |
| Pathway:           | Cell Cycle/DNA Damage; Cytoskeleton |       |          |  |
| Storage:           | Powder                              | -20°C | 3 years  |  |
|                    |                                     | 4°C   | 2 years  |  |
|                    | In solvent                          | -80°C | 6 months |  |
|                    |                                     | -20°C | 1 month  |  |

®

MedChemExpress

## SOLVENT & SOLUBILITY

|                 |                              | Solvent Mass<br>Concentration | 1 mg      | 5 mg      | 10 mg      |
|-----------------|------------------------------|-------------------------------|-----------|-----------|------------|
|                 | Preparing<br>Stock Solutions | 1 mM                          | 1.8702 mL | 9.3512 mL | 18.7024 mL |
| Stock Solutions | 5 mM                         | 0.3740 mL                     | 1.8702 mL | 3.7405 mL |            |
|                 |                              | 10 mM                         | 0.1870 mL | 0.9351 mL | 1.8702 mL  |

| BIOLOGICAL ACTIV          |   |  |  |  |
|---------------------------|---|--|--|--|
| Description               | KIF18A-IN-2 is a potent KIF18A inhibitor (IC <sub>50</sub> =28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer <sup>[1]</sup> .   |  |  |  |
| IC <sub>50</sub> & Target | IC <sub>50</sub> : 28 nM (KIF18A) <sup>[1]</sup>  |  |  |  |
| In Vivo                   | KIF18A-IN-2 (compound 23) (100 mg/kg; i.p., single) exhibits a significant and sustained pharmacodynamic response,<br>increasing the number of mitotic cells (pH3 positive cells) in tumor tissues for up to 24 hours <sup>[1]</sup> .Pharmacokinetic Parameters<br>of KIF18A-IN-2 in female CD-1 mice <sup>[1]</sup> . |  |  |  |
|                           | IP (100 mg/kg)  |  |  |  |
|                           | C <sub>max</sub> (μM) 12.6  |  |  |  |
|                           |   |  |  |  |

## Product Data Sheet

000

ŅΗ

O O N S ∕ H

0″

| AUC <sub>0-24</sub> (μM·h) | 147   |
|----------------------------|-------|
| C <sub>24h</sub> (μM)      | 2.9   |
| PPB (f <sub>u</sub> )      | 0.007 |

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| Animal Model:   | Female athymic nude mice (4-7 weeks; injected with human OVCAR-3 HGSOC cells) $^{[1]}$  |
|-----------------|---|
| Dosage:         | 100 mg/kg   |
| Administration: | i.p., single  |
| Result:         | Showed a significant and sustained pharmacodynamic response, increasing the number of mitotic cells (pH3 positive cells) in tumor tissues for up to 24 hours. |

## REFERENCES

[1]. Tamayo NA, et al. Targeting the Mitotic Kinesin KIF18A in Chromosomally Unstable Cancers: Hit Optimization Toward an In Vivo Chemical Probe. J Med Chem. 2022;65(6):4972-4990.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA